Agilent Technologies Inc.  announced a two-year research  collaboration agreement with Singapore’s Nucleic Acid Therapeutics Initiative (NATi), hosted by Agency  for Science, Technology and Research (A*STAR), to accelerate research into complex oligonucleotide (oligo) candidates, a promising frontier in precision therapeutics with potential applications across cardiovascular-metabolic, rare and infectious diseases. 

The global oligo therapeutics market exceeded $7 billion in 2025 and is projected to reach $18 billion  by 2030¹, driven by clinically validated DNA- and RNA-based therapies that continue to face analytical  challenges beyond liver-targeted delivery².  

Under this agreement, the collaboration will focus on developing end-to-end analytical and preparative workflows to support ligand-conjugated strategies, a new platform designed to extend oligo delivery  beyond the liver tissues, unlock access to extrahepatic tissues and expand the therapeutic addressable  market. 

By combining NATi’s extensive expertise in nucleic acid and chemical modifications with Agilent’s 1290  Infinity III Bio UHPLC system, InfinityLab Pro iQ Plus mass detector, Preparative HPLC system, 6545XT  AdvanceBio Quadrupole Time of Flight LC/MS, and Seahorse XF technologies, the collaboration will enable precise characterization, purification and quality assessment of lipid-modified oligo, a key  modality to accelerating more efficient preclinical development.  

“Lipid-conjugated oligonucleotides represent a promising next frontier in nucleic acid therapeutics,  particularly in expanding beyond hepatic delivery. Working with strategic partners like Agilent allows us  to tighten the value chain from research to clinic, accelerating the development of next-generation oligo  therapeutics that address areas of significant unmet medical need," said Dr Mohamed ElSayed,  Executive Director of Nucleic Acid Therapeutics Initiative (NATi).

“As oligo-based therapies continue to transform precision medicine, the ability to reliably analyze and  purify complex conjugates becomes increasingly critical. Our priority remains to help existing and new  biopharma customers accelerate new discoveries through research advancement. This collaboration is  yet another example of our commitment to investing in high-growth markets while delivering on  Agilent’s mission of improving the quality of life,” said Bharat Bhardwaj, Vice President of APAC Sales  at Agilent. 

The agreement includes structured training and access to advanced analytical capabilities at Agilent’s  Global Solution Development Center (GSDC) in Singapore, along with a broader suite of Agilent  analytical instruments.  

With more than 25 years of investment in Singapore, Agilent has grown its local presence to about 600  scientists, engineers and skilled professionals and operates an 860,000-square-foot manufacturing  facility recognized by the World Economic Forum. The expanding footprint underscores Agilent’s long term commitment to building local scientific capabilities, talent development and strengthening  Singapore’s position as a leading biomedical innovation hub for the region and beyond.